Until now, ischemic heart disease and chronic heart failure (HF) remain the biggest problem of health care in the world [1]. Due to diseases of cardiovascular system and reduction of heart pumping function millions of people live with HF [2]. There were developed many methods of HF treatment, but in some cases they do not solve the problem. One of the newest and prospective approaches is stem cells (SCs) transplantation. In most researches SCs transplantation led to significant improvement of contractile ability of the left ventricle (LV) myocardium in both animals [3] and people [4,5] at ischemia lesion. It was proved that stem cells improve patients' survival and quality of life [6]. However, several other studies have shown a chance of complications and adverse side effects at SCs transplantation [7][8][9]. These differences are explained by the use of SCs from various sources and, consequently, with different properties.Experiments on animals have shown an effectiveness of cord blood SCs in restoration of myocardial contractility [10][11][12][13]
MATERIALS AND METHODS. According to the data echocardiography we analyzed the changes of intracardiac hemodynamics in patients with decreased myocardial contractility, who underwent intravenous transplantation of cord blood stem cells in case of ineffective traditional conservative therapy schemes of heart failure (HF).
RESULTS. Left ventricular ejection fraction before cord blood stem cells transplantation was 22.0 ± 5.0%, 1 month after